Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 6Breast Neoplasms, Male 3Testicular Neoplasms 2Testicular Germ Cell Tumor 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Uterine Cervical Neoplasms 1Teratoma 1Seminoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Renal Pelvis and Ureter Urothelial Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, Follicular 1Lymphoma, AIDS-Related 1Inflammatory Breast Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Endodermal Sinus Tumor 1Central Nervous System Neoplasms 1Carcinoma, Embryonal 1

Interventions

Cisplatin 18Brachytherapy 14Radiotherapy 11Platinum 91,2-diaminocyclohexaneplatinum II citrate 9Radiation 7Paclitaxel 7aldesleukin 6Specimen Handling 6fludarabine phosphate 5fludarabine 5Magnetic Resonance Spectroscopy 5Cyclophosphamide 5Colposcopy 5Topotecan 4Immunoglobulin G 4Human Papillomavirus DNA Tests 4Fluorodeoxyglucose F18 4Disulfides 4Biopsy 4Bevacizumab 43-aminopyridine-2-carboxaldehyde thiosemicarbazone 4Trastuzumab 3Taxes 3Nivolumab 3Ipilimumab 3Congresses as Topic 3Carboplatin 3CTLA-4 Antigen 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Uterine Cervical Neoplasms × pegfilgrastim × Clear all
NCT01266447 2019-08-08

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
27 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡